Fasting could boost breast cancer treatment by triggering key hormonal and genetic changes, new research suggests. Estrogen-receptor–positive breast cancer is the most common form worldwide, and endocrine therapies that block or lessen estrogen are a primary treatment. While these drugs are powerful, some tumors eventually resist therapy after years of use, prompting researchers to explore strategies that both enhance effectiveness and extend response duration. Diet, particularly controlled short fasts, is gaining interest as a potential factor. A recent study published in Nature provides new evidence that fasting can prompt hormonal and genetic shifts in tumor cells, reinforcing the impact of endocrine therapy. These findings open the door to safer, more practical combination approaches in the near future.
Fasting enhances breast cancer treatment when paired with endocrine therapy
Many breast cancers rely on the estrogen receptor to grow. One endocrine drug, tamoxifen, aims to block this pathway. The new research shows that severe or intermittent fasting can amplify the drug’s effects on cancer cells by driving genetic and hormonal changes. In animal experiments, tumors in fasted animals treated with tamoxifen shrank substantially more than those in animals that received tamoxifen alone.
A central explanation is fasting’s impact on the tumor epigenome. Epigenetics involves chemical markers that control which genes are turned on or off. Fasting caused broad epigenetic changes, effectively “re-educating” breast cancer cells so they became more sensitive to treatment and less capable of growing.
The glucocorticoid receptor plays a pivotal role
A key finding is the involvement of the glucocorticoid receptor, which is activated by natural body hormones like cortisol. Fasting raises cortisol levels, increasing glucocorticoid receptor activation inside cancer cells. When this receptor is activated, a set of genes that suppress tumor growth is turned on, while the AP-1 protein group—which often promotes cancer cell proliferation—is suppressed. This combination makes tumor cells less resistant to therapy and less able to survive.
Importantly, removing the glucocorticoid receptor from cancer cells negated the enhanced tamoxifen effect seen with fasting, highlighting the receptor’s driving role. Activation of the progesterone receptor also adds another layer of anti-tumor activity.
Fasting boosts progesterone receptor activity
In addition to glucocorticoid signaling, fasting raised progesterone levels in mice and in humans following a fasting-mimicking diet. This activated the progesterone receptor, a known anti-tumor factor in estrogen receptor–positive breast cancer. While the study emphasized the glucocorticoid pathway, it also points to a meaningful contribution from the progesterone pathway.
Brief fasting-mimicking diets show promise in patients
The researchers looked at hormone-receptor–positive breast cancer patients who voluntarily followed a short fasting-mimicking diet alongside endocrine therapy. Blood samples after the diet showed rises in cortisol and progesterone, echoing the mouse data. Biopsies taken after the diet revealed stronger glucocorticoid receptor gene engagement and lower markers of cell division in tumor tissue, supporting the idea that even brief, controlled dietary changes can trigger significant biological shifts in breast tumors.
Steroid drugs may mimic fasting effects
Interestingly, the team found that certain steroids could replicate fasting’s benefits. Dexamethasone, a synthetic glucocorticoid commonly used to reduce inflammation, when given with tamoxifen, produced a comparable anti-tumor response to fasting. Tumors shrank more and remained responsive longer even after therapy stopped. This suggests a potential alternative approach for patients who find long-term fasting difficult, though rigorous safety studies are essential before any regimen could be recommended.
Implications for future breast cancer treatment
Overall, the work indicates that to boost endocrine therapy in estrogen receptor–positive breast cancer, targeting the glucocorticoid receptor is crucial. Steroid-based strategies might offer a parallel path to fasting and fasting-mimicking diets, but more evidence is needed before clinical approval. Still, these findings provide a strong hint that overcoming treatment resistance—one of the biggest challenges in breast cancer therapy—may be achievable through hormonal and epigenetic modulation alongside conventional treatments.
Thought-provoking notes for readers
- The idea that diet can influence cancer treatment may be controversial to some. What are your thoughts on integrating dietary strategies with standard cancer therapies?
- If fasting or steroids can mimic fasting effects, what considerations should guide patient safety, quality of life, and long-term outcomes?
- How should clinicians balance potential benefits with risks when exploring these approaches in real-world settings?
